Overview
Lung Cancer
1.Role of molecular markers in the prognosis and therapy of lung cancer
2.Genomic analysis lung cancer mutations
Esophageal Cancer
1.Role of molecular markers in the prognosis and therapy of esophageal cancer
2.Genomic analysis esophageal cancer mutations
1.Role of molecular markers in the prognosis and therapy of lung cancer
2.Genomic analysis lung cancer mutations
Esophageal Cancer
1.Role of molecular markers in the prognosis and therapy of esophageal cancer
2.Genomic analysis esophageal cancer mutations
Current Appointments & Affiliations
Gary Hock Distinguished Professor of Surgery
·
2013 - Present
Surgery, Cardiovascular and Thoracic Surgery,
Surgery
Professor of Surgery
·
2007 - Present
Surgery, Cardiovascular and Thoracic Surgery,
Surgery
Member of the Duke Cancer Institute
·
2012 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Publications
Pembrolizumab, Radiotherapy, and Chemotherapy in Neoadjuvant Treatment of Malignant Esophago-gastric Diseases (PROCEED): A single-arm phase 2 trial.
Journal Article Cancer · December 15, 2025 INTRODUCTION: Esophagogastric cancers are common and carry a poor prognosis. A standard option for locally advanced disease has been neoadjuvant chemoradiation (CRT) followed by surgical resection. The primary goal of this study was to investigate whether ... Full text Link to item CiteGastric Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology.
Journal Article J Natl Compr Canc Netw · May 2025 Gastric cancer is the fifth leading cause of cancer-related deaths worldwide. Over 95% of gastric cancers are adenocarcinomas, which are typically classified based on anatomic location and histologic type. Gastric cancer generally carries a poor prognosis ... Full text Link to item CiteSystematic Review of Stereotactic Ablative Radiotherapy (SABR)/Stereotactic Body Radiation Therapy (SBRT) for Treatment of High-Risk Patients with Stage I Non-Small Cell Lung Cancer.
Journal Article Seminars in thoracic and cardiovascular surgery · March 2025 Stereotactic ablative radiotherapy (SABR) has emerged as an alternative, non-surgical treatment for high-risk patients with stage I non-small cell lung cancer (NSCLC) with increased use over time. The American Association for Thoracic Surgery (AATS) Clinic ... Full text CiteRecent Grants
Clinical Oncology Research Career Development Program
ResearchMentor · Awarded by National Institutes of Health · 2009 - 2015Phase I/II Trial of ZD1839 and Celecoxib in Ex-Smokers
ResearchCo Investigator · Awarded by National Institutes of Health · 2002 - 2007Genetics, Inflammation & Post-op Cognitive Dysfunction
ResearchCo Investigator · Awarded by National Institutes of Health · 1999 - 2006View All Grants
Education, Training & Certifications
Columbia University ·
1987
M.D.